Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
...OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it received...Launch of Immune Report Card
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) — OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...OmniSeq Receives New York CLEP Approval for 144 Gene Comprehensive Panel and Partners with Cure Forward to Advance Precision Medicine for Cancer Patients
BUFFALO, NY – June 28, 2016 – OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq ComprehensiveSM panel, a 144 gene, pan-cancer, next-generation sequencing (NGS) tumor...
Follow Us on Twitter
Immune Report Card®: New Test Matches Patients With Immunotherapies Likely to Work Best | Roswell Park Comprehensive Cancer Center https://t.co/M3a34gfbQG
Proud that OmniSeq has met the rigorous standards needed to become an NCI-MATCH participating lab. Working hard with our colleagues at LabCorp to bring this testing to NCORP sites across the country! https://t.co/qUQTFidjek
OmniSeq Advance "All I Want": https://t.co/NwtMmpXspL via @YouTube
Excellent work being done at UCSD by @Dr_R_Kurzrock to incorporate transcriptomics and clinical trial matching!
"I’m not saying that on the basis of this one trial transcriptomics can become standard of care but the #WINTHER trial definitely suggests transcriptomics should be an important part of additional clinical trials" @Dr_R_Kurzrock
@WIN_Consortium #ASCO18 https://t.co/GSJ7pbu2Cq